Y-mAbs Therapeutics Inc YMAB
News
Y-mAbs Presents Neuroblastoma Research on Naxitamab and SADA PRIT Technology Platform at AACR Special Conference on Advances in Pediatric Cancer Research
Y-mAbs to Participate in Upcoming Investor Conferences in September
Y-mAbs Reports Second Quarter 2024 Financial Results and Recent Corporate Developments
Y-mAbs to Participate in Upcoming Investor Conferences in August
Y-mAbs Announces Second Quarter 2024 Conference Call and Webcast
Pomerantz LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of Stock of Y-mAbs Therapeutics, Inc. - YMAB
Y-mAbs Therapeutics New Drug Application Gets FDA Clearance